- Home
- SOR vs EBS Comparison
SOR vs EBS Comparison
Compare SOR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- EBS
- Stock Information
- Founded
- SOR 1968
- EBS 1998
- Country
- SOR United States
- EBS United States
- Employees
- SOR N/A
- EBS N/A
- Industry
- SOR Investment Managers
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- EBS Health Care
- Exchange
- SOR Nasdaq
- EBS Nasdaq
- Market Cap
- SOR 368.0M
- EBS 423.6M
- IPO Year
- SOR N/A
- EBS 2006
- Fundamental
- Price
- SOR $45.87
- EBS $10.48
- Analyst Decision
- SOR
- EBS Strong Buy
- Analyst Count
- SOR 0
- EBS 2
- Target Price
- SOR N/A
- EBS $13.50
- AVG Volume (30 Days)
- SOR 16.2K
- EBS 1.4M
- Earning Date
- SOR 01-01-0001
- EBS 10-29-2025
- Dividend Yield
- SOR 7.24%
- EBS N/A
- EPS Growth
- SOR N/A
- EBS N/A
- EPS
- SOR 6.50
- EBS 1.35
- Revenue
- SOR N/A
- EBS $788,900,000.00
- Revenue This Year
- SOR N/A
- EBS N/A
- Revenue Next Year
- SOR N/A
- EBS $19.24
- P/E Ratio
- SOR $6.41
- EBS $7.77
- Revenue Growth
- SOR N/A
- EBS N/A
- 52 Week Low
- SOR $36.41
- EBS $4.02
- 52 Week High
- SOR $42.75
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- SOR 60.74
- EBS 54.80
- Support Level
- SOR $44.99
- EBS $9.21
- Resistance Level
- SOR $46.00
- EBS $13.41
- Average True Range (ATR)
- SOR 0.64
- EBS 0.82
- MACD
- SOR 0.01
- EBS 0.17
- Stochastic Oscillator
- SOR 88.50
- EBS 32.84
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.